Table 3Large Observational Cohort Studies Of Combination Antiretroviral Regimens On Risk Of Mother-to-Child Transmission Of HIV Infection

Study, yearLocationInterventionsNumber enrolled (mother-infant pairs)Mother-to-child transmission rateCesarean section rateBreastfeeding rateInternal validity rating
Italian Register, 200248 ItalyA. No antiretroviralsA. 2,440A. 18.5%97.7% overall, 69.9% elective2.8% overallGOOD
B. ZDV monotherapyB. 743B. 6.1%
C. 2 or more drug therapyC. 248C. 1.6%
Women and Infants Transmission Study, 200237 USA. No antiretroviralsA. 396A. 20.0%A. 20.1%No infant was breastfedGOOD
B. ZDV monotherapyB. 710B. 10.4%B. 24.0%
C. 2 drug therapyC. 186C. 3.8%C. 33.8%
D. HAARTD. 250D. 1.2%D. 44.4%
European Collaborative Study, 2005149 EuropeA. No antiretroviralsA. 157A. 11.5%16% emergency, 61% elective2% overall (through 2000)GOOD
B. HAARTB. 918B. 1.2%
French Perinatal Study (Mandelbrot et al, 2001)150 FranceA. ZDV monotherapy (historical control group)A. 858A. 6.8%A: 16% electiveA. 0.3%FAIR. Used historical controls
B. Lamivudine + ZDV from 32 weeks in pregnancy and to the child for 6 weeksB. 437B. 1.6%B: 22% electiveB. 0.5%

HAART, highly active antiretroviral therapy; ZDV, zidovudine.

From: 3, Results

Cover of Screening for Human Immunodeficiency Virus in Pregnant Women
Screening for Human Immunodeficiency Virus in Pregnant Women [Internet].
Evidence Syntheses, No. 39.
Chou R, Smits AK, Huffman LH, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.